In summary, our results demonstrate that MEX3A may promote NPC development and progression via the miR-3163/SCIN axis by regulating NF-κB signaling, thus providing a potential target for NPC treatment. This evidence concerns the gene NFKB1 and nasopharyngeal carcinoma.